![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Guangdong Xinyaguang Cable
001382
Haimo Technologies Group Corp.
300084
Shaoyang Victor Hydraulics
301079
4
KLT
831689
5
Qingdao Tianneng Heavy Industries
300569
US Stock MarketDetailed Quotes
KPTI Karyopharm Therapeutics
- 6.420
- +0.280+4.56%
Close Mar 21 16:00 ET
- 6.420
- 0.0000.00%
Post 16:13 ET
54.03MMarket Cap-0.46P/E (TTM)
6.560High6.060Low87.31KVolume6.070Open6.140Pre Close546.05KTurnover1.21%Turnover RatioLossP/E (Static)8.42MShares24.75052wk High-0.29P/B46.52MFloat Cap5.56052wk Low--Dividend TTM7.25MShs Float735.075Historical High--Div YieldTTM8.14%Amplitude5.560Historical Low6.254Avg Price1Lot Size
Karyopharm Therapeutics Stock Forum
Sign in to post a comment
$Karyopharm Therapeutics (KPTI.US)$
XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC
Logo (PRNewsfoto/Antengene Corporation Limited)
NEWS PROVIDED BY
Antengene Corporation Limited
Mar 05, 2025, 00:00 ET
- XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia.
- From the second half of 2024 to now, XPOVIO® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene's c...
XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC
Logo (PRNewsfoto/Antengene Corporation Limited)
NEWS PROVIDED BY
Antengene Corporation Limited
Mar 05, 2025, 00:00 ET
- XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia.
- From the second half of 2024 to now, XPOVIO® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene's c...
3
1
🔵Watchlist, FEBRUARY 26,2025, Wednesday. NFA -DrJag8. NOTE: I won’t entertain questions. Do your DD.
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free c...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free c...
58
13
6
$Karyopharm Therapeutics (KPTI.US)$ the management team is mediocre and incompetent
$Karyopharm Therapeutics (KPTI.US)$ a bunch of incompetent persons running the company
$Karyopharm Therapeutics (KPTI.US)$ extreme incompetence for the management
$Karyopharm Therapeutics (KPTI.US)$ the stock should be delisted
$Karyopharm Therapeutics (KPTI.US)$ better buy now, price will go up to 2usd
1
$Karyopharm Therapeutics (KPTI.US)$ buy now lots of good news
3
$Karyopharm Therapeutics (KPTI.US)$
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
Karyopharm Therapeutics (Nasdaq: KPTI)announced a change in co-primary endpoint for its Phase 3 SENTRY Trial in myelofibrosis, replacing TSS50 with Absolute Total Symptom Score (Abs-TSS) following FDA feedback. The trial's sample size will increase to approximately 350 patients, with top-line data expected in 2H 2025.
Phase 1 trial data showed pr...
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
Karyopharm Therapeutics (Nasdaq: KPTI)announced a change in co-primary endpoint for its Phase 3 SENTRY Trial in myelofibrosis, replacing TSS50 with Absolute Total Symptom Score (Abs-TSS) following FDA feedback. The trial's sample size will increase to approximately 350 patients, with top-line data expected in 2H 2025.
Phase 1 trial data showed pr...
2
1
$Karyopharm Therapeutics (KPTI.US)$ Reuters· 5 mins ago
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 Sentry Trial in Myelofibrosis
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 Sentry Trial in Myelofibrosis
No comment yet
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
ColdJoke : HK 6996. That revenue mainly goes to Antengene. We really got sucked badly and going to delist![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
.